<PAGE>
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant [X]
Filed by Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
[ X ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Section 240.14a-11(c) or Section
240.14a-12
-------------------------------
BIOSANTE PHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its Charter)
-------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
-------------------------------
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
<PAGE>
[LOGO]
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD JUNE 13, 2000
-------------------------
TO THE SHAREHOLDERS OF BIOSANTE PHARMACEUTICALS, INC.:
The Annual and Special Meeting of Shareholders of BioSante
Pharmaceuticals, Inc., a Wyoming corporation, will be held on Tuesday, June
13, 2000, at 2:00 p.m., local time, at the American Airlines Admirals Club,
Terminal 3, O'Hare International Airport, Chicago, Illinois, for the
following purposes:
1. To elect nine persons to serve as directors until our next annual
meeting of shareholders or until their respective successors are
elected and qualified.
2. To consider a proposal to amend our 1998 Stock Option Plan to
increase the number of shares of common stock reserved for issuance
under the plan by 2,000,000 shares, from 5,000,000 shares to
7,000,000 shares.
3. To consider a proposal to ratify the appointment of Deloitte &
Touche L.L.P. as our independent auditors for the fiscal year
ending December 31, 2000.
4. To transact such other business as may properly come before the
meeting or any adjournment thereof.
Only shareholders of record at the close of business on April 28, 2000
will be entitled to notice of, and to vote at, the meeting and any
adjournments thereof. It is important that your shares be represented and
voted at the meeting. Please mark, sign, date and mail the enclosed proxy
card in the postage-paid envelope provided.
By Order of the Board of Directors,
/s/ Phillip B. Donenberg
Phillip B. Donenberg
SECRETARY
May 1, 2000
Lincolnshire, Illinois
================================================================================
IMPORTANT: THE PROMPT RETURN OF YOUR PROXY CARD WILL SAVE THE COMPANY THE
EXPENSE OF FURTHER REQUESTS FOR PROXIES TO ENSURE A QUORUM AT THE MEETING.
A SELF-ADDRESSED ENVELOPE IS ENCLOSED FOR YOUR CONVENIENCE. NO POSTAGE IS
REQUIRED IF MAILED WITHIN THE UNITED STATES OR FROM CANADA.
================================================================================
<PAGE>
TABLE OF CONTENTS
-----------------
<TABLE>
<CAPTION>
Page
<S> <C>
INFORMATION CONCERNING THE ANNUAL AND SPECIAL MEETING......................................... 1
Date, Time, Place and Purposes............................................................. 1
Shareholders Entitled to Vote.............................................................. 1
Proxies.................................................................................... 1
Revocation of Proxies...................................................................... 1
Quorum Requirement......................................................................... 1
Vote Required.............................................................................. 2
Proxy Solicitation Costs................................................................... 2
SECURITY OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT................................... 3
ELECTION OF DIRECTORS (Proposal 1)............................................................ 5
Number of Directors........................................................................ 5
Nominees for Director...................................................................... 5
Vote Required.............................................................................. 5
Board Recommendation....................................................................... 6
Information About Nominees................................................................. 6
Other Information About Nominees........................................................... 7
Information About your Board of Directors and its Committees............................... 8
Director Compensation...................................................................... 8
EXECUTIVE COMPENSATION AND OTHER BENEFITS..................................................... 9
Summary of Cash and Other Compensation..................................................... 9
Option Grants in Last Fiscal Year.......................................................... 10
Aggregated Option Exercises In Last Fiscal Year and Fiscal Year-End Option Values.......... 11
Employment and Severance Agreements........................................................ 11
Change in Control Arrangements............................................................. 12
RELATED PARTY RELATIONSHIPS AND TRANSACTIONS.................................................. 13
Director Relationships..................................................................... 13
May 1999 Private Placement................................................................. 13
PROPOSAL TO AMEND OUR 1998 STOCK OPTION PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON
STOCK RESERVED FOR ISSUANCE (Proposal 2)...................................................... 14
Proposed Amendment......................................................................... 14
Purpose of the Amendment................................................................... 14
Summary of the 1998 Stock Option Plan...................................................... 14
Federal Income Tax Consequences............................................................ 16
Options Under the Option Plan.............................................................. 18
Vote Required.............................................................................. 18
Board Recommendation....................................................................... 18
RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS (Proposal 3)................................ 19
Appointment of Auditors.................................................................... 19
Vote Required.............................................................................. 19
Board Recommendation....................................................................... 19
OTHER MATTERS................................................................................. 20
Section 16(a) Beneficial Ownership Reporting Compliance.................................... 20
Shareholder Proposals For 2001 Annual Meeting.............................................. 20
Other Business............................................................................. 20
Copies of 2000 Annual Report............................................................... 20
</TABLE>
i
<PAGE>
[LOGO]
75 OLDE HALF DAY ROAD
LINCOLNSHIRE, ILLINOIS 60069
----------------------
PROXY STATEMENT FOR
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
JUNE 13, 2000
----------------------
INFORMATION CONCERNING THE ANNUAL AND SPECIAL MEETING
DATE, TIME, PLACE AND PURPOSES
The meeting will be held on Tuesday, June 13, 2000, at 2:00 p.m., local time, at
the American Airlines Admirals Club, Terminal 3, O'Hare International Airport,
Chicago, Illinois, for the purposes set forth in the Notice of Meeting.
SHAREHOLDERS ENTITLED TO VOTE
Shareholders of record at the close of business on April 28, 2000 will be
entitled to vote at the meeting. As of that date, there were 52,684,526 shares
of our common stock and 4,766,025 shares of our class C stock outstanding. Each
share of our common stock and class C stock is entitled to one vote on each
matter to be voted on at the Annual and Special Meeting. Shareholders are not
entitled to cumulate voting rights.
PROXIES
This proxy statement is being mailed to our shareholders beginning on or about
May 1, 2000 in connection with the solicitation of proxies by your Board of
Directors for use at the Annual and Special Meeting of Shareholders.
Your vote is important. A proxy card is enclosed for your use. YOU ARE SOLICITED
ON BEHALF OF YOUR BOARD OF DIRECTORS, TO MARK, SIGN, DATE AND RETURN THE PROXY
CARD IN THE ACCOMPANYING ENVELOPE. No postage is required if mailed within the
United States or from Canada.
Proxies will be voted as specified by you. Signed proxies that lack any
specification will be voted in favor of all of the proposals set forth in the
Notice of Meeting and in favor of the election of all of the nominees for
director listed in this proxy statement.
YOUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR THE APPROVAL OF ALL OF THE
PROPOSALS SET FORTH IN THE NOTICE OF MEETING AND FOR ALL OF THE NOMINEES FOR
DIRECTOR LISTED IN THIS PROXY STATEMENT.
REVOCATION OF PROXIES
Any shareholder giving a proxy may revoke it at any time prior to its use at the
Annual and Special Meeting by:
- - giving written notice of your revocation to our Secretary,
- - filing a duly executed proxy bearing a later date with our Secretary, or
- - appearing at the Annual and Special Meeting and filing written notice of
revocation with our Secretary prior to use of the proxy.
QUORUM REQUIREMENT
The presence at the Annual and Special Meeting, in person or by proxy, of two
holders of each of our outstanding common stock and class C stock at the Annual
and Special Meeting will constitute a quorum for the transaction of business at
the Annual and Special Meeting.
<PAGE>
VOTE REQUIRED
Assuming a quorum is represented at the Annual and Special Meeting, either in
person or by proxy, the election of the nine nominees for director requires the
affirmative vote of a plurality of the shares of common stock and class C stock,
voting together as a single class, present and entitled to vote in person or by
proxy, and the approval of the other proposals described in this proxy
statement, require the affirmative vote of the holders of a majority of the
shares of common stock and class C stock, voting together as a single class,
present and entitled to vote in person or by proxy. Shares represented by a
proxy card including any broker non-votes on a matter will be treated as shares
not entitled to vote on that matter, and thus will not be counted in determining
whether that matter has been approved. A "broker non-vote" is a card returned by
a broker on behalf of its beneficial owner customer that is not voted on a
particular matter because voting instructions have not been received, and the
broker has no discretionary authority to vote. Shares represented by a proxy
card voted as abstaining on any of the proposals will be treated as shares
present and entitled to vote that were not cast in favor of a particular matter,
and thus will be counted as votes against that matter. Signed proxies that lack
any specification will be voted in favor of all of the proposals set forth in
the Notice of Meeting and in favor of the election of all of the nine nominees
for directors listed in this proxy statement.
PROXY SOLICITATION COSTS
The cost of soliciting proxies, including the preparation, assembly and mailing
of proxies and soliciting material, as well as the cost of forwarding this
material to the beneficial owners of our capital stock will be borne by us. Our
directors, officers and regular employees may, without compensation other than
their regular compensation, solicit proxies by telephone, facsimile, telegraph
or personal conversation. We may reimburse brokerage firms and others for
expenses in forwarding proxy materials to the beneficial owners of our capital
stock.
2
<PAGE>
SECURITY OWNERSHIP OF PRINCIPAL SHAREHOLDERS
AND MANAGEMENT
--------------
The following table sets forth information known to us with respect
to the beneficial ownership of each class of our capital stock as of March
31, 2000 for (1) each person known by us to beneficially own more than 5% of
any class of our voting securities, (2) each of the executive officers named
in the Summary Compensation Table on page 9 under the heading "Executive
Compensation and Other Benefits," (3) each of our directors and (4) all of
our executive officers and directors as a group. Except as otherwise
indicated, we believe that each of the beneficial owners of our capital stock
listed below, based on information provided by these owners, has sole
investment and voting power with respect to its shares, subject to community
property laws where applicable.
<TABLE>
<CAPTION>
PERCENT OF
COMMON STOCK CLASS C STOCK COMMON STOCK AND TOTAL
------------------------ --------------------- COMMON STOCK VOTING
NAME NUMBER PERCENT NUMBER PERCENT EQUIVALENTS (1) POWER (2)
- ----------------------------------- -------------- ------- --------- -------- --------------- ----------
<S> <C> <C> <C> <C> <C> <C>
Stephen M. Simes (3)............... 1,943,139 (4) 3.6% -- -- 1,943,139 3.3%
Louis W. Sullivan, M.D. (3)........ -- -- 1,000,000 21.0% 1,000,000 1.7%
Edward C. Rosenow III, M.D. (3).... 100,000 (5) * -- -- 100,000 *
Victor Morgenstern (3)............. 3,750,000 (6) 7.0% -- -- 3,750,000 6.4%
Fred Holubow (3)................... 375,000 (7) * -- -- 375,000 *
Ross Mangano (3)................... 11,250,000 (8) 19.9% -- -- 11,250,000 18.4%
Angela Ho (3)...................... 700,000 (9) 1.3% 1,000,000 21.0% 1,700,000 3.0%
Peter Kjaer (3).................... -- -- -- -- -- --
Avi Ben-Abraham, M.D. (3).......... 11,129,800 (10) 21.0% -- -- 11,129,800 19.3%
Phillip B. Donenberg (3)........... 427,750 (11) * -- -- 427,750 *
JO & Co............................ 11,250,000 (12) 19.9% -- -- 11,250,000 18.4%
Hans Michael Jebsen................ 4,250,000 (13) 8.0% 1,000,000 21.0% 5,250,000 9.0%
King Cho Fung...................... 3,500,000 (14) 6.6% 625,000 13.1% 4,125,000 7.1%
Marcus Jebsen...................... 1,750,000 (15) 3.3% 500,000 10.5% 2,250,000 3.9%
All executive officers and
directors as a group (10 persons).. 29,675,689 (16) 49.2% 2,000,000 42.0% 31,675,689 48.7%
</TABLE>
- ---------------------
* less than 1%.
(1) In calculating an individual's percentage ownership, conversion of any
shares of our class C stock owned by the individual is assumed for
purposes of the calculation.
(2) In calculating the percent of total voting power, the voting power of
shares of our class C stock and our common stock is combined.
(3) Address: 175 Olde Half Day Road, Lincolnshire, IL 60069.
(4) Mr. Stephen M. Simes' beneficial ownership includes 1,568,139 shares of
common stock issuable upon exercise of stock options and 125,000 shares
of common stock issuable upon exercise of a warrant.
(5) Dr. Edward C. Rosenow's beneficial ownership includes 100,000 shares of
common stock issuable upon exercise of stock options.
(6) Mr. Victor Morgenstern's beneficial ownership includes: (1) 750,000
shares of common stock issuable upon exercise of a warrant, (2) 250,000
shares of common stock issuable upon exercise of a warrant and 500,000
shares of common stock held by Mr. Morgenstern's wife as trustee of the
Morningstar Trust, as to
3
<PAGE>
which Mr. Morgenstern disclaims control, direction or beneficial
ownership, and (3) 250,000 shares of common stock issuable upon
exercise of a warrant and 500,000 shares of common stock held by
Resolute Partners. Victor Morgenstern is a partner of Resolute
Partners.
(7) Mr. Fred Holubow's beneficial ownership includes 125,000 shares of
common stock upon exercise of a warrant.
(8) Mr. Ross Mangano's beneficial ownership includes 3,750,000 shares of
common stock issuable upon exercise of a warrant and 7,500,000 shares
of common stock held by JO & Co. See note (12) below.
(9) Ms. Angela Ho's beneficial ownership includes 100,000 shares of common
stock issuable upon exercise of stock options.
(10) Dr. Avi Ben-Abraham's beneficial ownership includes 200,000 shares of
common stock issuable upon exercise of stock options. Dr. Ben-Abraham
has entered into an agreement limiting the voting rights with respect
to his shares of common stock in certain circumstances. His percentage
ownership has been calculated without taking these restrictions into
account.
(11) Mr. Phillip B. Donenberg's beneficial ownership includes 427,750 shares
of common stock issuable upon exercise of stock options.
(12) Includes 3,750,000 shares of common stock issuable upon exercise of a
warrant. Ross Mangano, a director of BioSante, has sole voting power
over these shares. See note (8) above. The address for JO & Co. is 112
West Jefferson Boulevard, Suite 613, South Bend, Indiana 46634.
(13) Mr. Hans Michael Jebsen's beneficial ownership includes 750,000 shares
of common stock issuable upon exercise of a warrant. Mr. Jebsen's
address is c/o Jebsen & Co. Ltd., 28/F Caroline Center, 28 Yun Ping
Road, Causeway Bay, Hong Kong.
(14) Mr. King Cho Fung's beneficial ownership includes 750,000 shares of
common stock issuable upon exercise of a warrant. Mr. Fung's address is
Room 2101, Lyndhurst Tower, One Lyndhurst Terrace, Central Hong Kong.
(15) Mr. Marcus Jebsen's beneficial ownership includes 250,000 shares of
common stock issuable upon exercise of a warrant. Mr. Jebsen's address
is c/o Jebsen & Co. Ltd., 28/F Caroline Center, 28 Yun Ping Road,
Causeway Bay, Hong Kong.
(16) The amount beneficially owned by all current directors and executive
officers as a group includes 9,395,889 shares issuable upon exercise of
warrants and stock options held by these individuals and 4,250,000
shares issuable upon exercise of warrants held by entities affiliated
with these individuals. See notes (6), (8) and (12) above.
4
<PAGE>
ELECTION OF DIRECTORS
(PROPOSAL 1)
------------------
NUMBER OF DIRECTORS
Our bylaws provide that your Board of Directors will consist of at least one
member, or such other number as may be determined by your Board of Directors.
The number of directors is currently set at nine.
NOMINEES FOR DIRECTOR
In connection with our May 1999 private placement, we entered into a
Shareholders' Agreement with the investor parties thereto. This agreement
contains, among other things, a voting agreement with respect to the election
of directors. Under the Shareholders' Agreement, we agreed that our Board of
Directors will consist of not less than three nor more than 12 directors and
that so long as Avi Ben-Abraham, M.D. holds at least 10% of our outstanding
capital stock, he will be entitled to be nominated as a director. Certain of
our major investors located in Hong Kong agreed that at the two general
elections for directors subsequent to the date of the closing of the May 1999
private placement, they will, subject to certain exceptions, vote all of
their shares of capital stock to elect Dr. Ben-Abraham as a director.
In addition, the holders of a majority of the shares of our capital stock
held by the lead investors in the May 1999 private placement are entitled to
nominate three members of our Board of Directors, and all of the parties to
the Shareholders' Agreement must vote their shares of our capital stock to
elect the nominees appointed by these investors to our Board of Directors.
These investors have designated Victor Morgenstern, Fred Holubow and Ross
Mangano as their directors.
Finally, under the Shareholders' Agreement, the holders of a majority of the
shares of our capital stock held by certain major investors located in Hong
Kong, are entitled to nominate up to three members of our Board of Directors,
and all parties to the Shareholders' Agreement must vote their shares of our
capital stock to elect the nominees appointed by these investors to the Board
of Directors. These major investors located in Hong Kong have designated
Angela Ho and Peter Kjaer as their directors.
The right to nominate up to three directors each held by the lead investors
and the Hong Kong investors will terminate immediately prior to the later of:
(1) the third general election of directors subsequent to May 6, 1999, the
date of the closing of the May 1999 private placement or (2) March 31, 2001.
These investors and your Board of Directors have nominated the following
individuals to serve as our directors until the next annual meeting of our
shareholders or until their successors are elected and qualified. All of the
nominees named below are current members of your Board of Directors.
* Louis W. Sullivan, M.D.
* Stephen M. Simes
* Victor Morgenstern
* Fred Holubow
* Ross Mangano
* Edward C. Rosenow III, M.D.
* Angela Ho
* Peter Kjaer
* Avi Ben-Abraham, M.D.
Proxies can only be voted for the number of persons named as nominees in this
proxy statement, which is nine.
VOTE REQUIRED
Assuming a quorum is represented at the Annual and Special Meeting, either in
person or by proxy, the election of a nominee for director
5
<PAGE>
requires the affirmative vote of a plurality of the shares of common stock
and class C stock represented in person or by proxy at the Annual and Special
Meeting, voting together as a single class.
BOARD RECOMMENDATION
Your Board of Directors recommends a vote FOR the election of all of the
nominees named above. In the absence of other instructions, the proxies will
be voted FOR the election of all of these nominees.
If, prior to the Annual and Special Meeting your Board of Directors should
learn that any nominee will be unable to serve for any reason, the proxies
that otherwise would have been voted for this nominee will be voted for a
substitute nominee as selected by your Board of Directors. Alternatively, the
proxies, at your Board's discretion, may be voted for that fewer number of
nominees as results from the inability of any nominee to serve. Your Board of
Directors has no reason to believe that any of the nominees will be unable to
serve.
INFORMATION ABOUT NOMINEES
The following table sets forth the name, age and principal
occupation of each nominee for director, as of April 15, 2000, as well as how
long each nominee has served as a director of BioSante.
<TABLE>
<CAPTION>
DIRECTOR
NAME OF NOMINEE AGE PRINCIPAL OCCUPATION SINCE
- -------------------------------------- --- ------------------------------------------ --------
<S> <C> <C> <C>
Louis W. Sullivan, M.D. (1)(2)(3)..... 66 President of the Morehouse School of 1996
Medicine and Chairman of the Board of
Directors of BioSante
Stephen M. Simes...................... 48 Vice Chairman, President and Chief 1998
Executive Officer of BioSante
Victor Morgenstern (2)................ 56 Partner and Chairman of Harris 1999
Associates, L.P.
Fred Holubow (3)...................... 60 Vice President of Pegasus Associates 1999
Ross Mangano (1)...................... 53 President of Oliver Estate, Inc. 1999
Edward C. Rosenow III, M.D. (3)....... 65 Master Fellow of the American College of 1997
Physicians and the American College of
Chest Physicians
Angela Ho (2)......................... 46 Vice Chairman and Chief Managing Officer 1998
of Jet-Asia Ltd.
Peter Kjaer (1)....................... 38 President and Chief Executive Officer of 1999
Jet-Asia Ltd.
Avi Ben-Abraham, M.D.................. 42 Independent Consultant 1996
</TABLE>
- ------------------
(1) Member of the Audit and Finance Committee
(2) Member of the Compensation Committee
(3) Member of the Scientific Review Committee
6
<PAGE>
OTHER INFORMATION ABOUT NOMINEES
THE HONORABLE LOUIS W. SULLIVAN, M.D. has been our Chairman of the Board of
Directors since March 1998 and has been a director of our company since its
formation. Dr. Sullivan served as Secretary of Health and Human Services in
the cabinet of President George Bush from 1989 to 1993. Since retiring from
the Bush Administration, Dr. Sullivan has been President of the Morehouse
School of Medicine in Atlanta, Georgia. He had previously served as President
and Dean of the School from 1981 to 1985. Since 1993, Dr. Sullivan has served
and continues to serve on the Boards of several large U.S. corporations,
including 3M Corp., Bristol-Myers Squibb, Cigna, General Motors Corporation,
Georgia Pacific Corp. and Household International Inc.
STEPHEN M. SIMES has served as our Vice-Chairman, President and a director of
our company since January 20, 1998 and Chief Executive Officer since March
1998. From October 1994 to January 1997, Mr. Simes was President, Chief
Executive Officer and a Director of Unimed Pharmaceuticals, Inc., a company
with a product focus on infectious diseases, AIDS, endocrinology and
oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief
Executive Officer of Gynex Pharmaceuticals, Inc., a company which
concentrated on the AIDS, endocrinology, urology and growth disorders
markets. In 1993, Gynex was acquired by Bio-Technology General Corp., and
from 1993 to 1994, Mr. Simes served as Senior Vice President and Director of
Bio-Technology General Corp. Mr. Simes' career in the pharmaceutical industry
started in 1974 with G.D. Searle & Co.
VICTOR MORGENSTERN was elected a director of our company in July 1999. Mr.
Morgenstern has more than 31 years of investment experience and is a partner
and chairman of Harris Associates L.P., a Chicago, Illinois-based investment
management firm since 1976. He is a director of Nvest Companies, L.P. and a
trustee of the Illinois Institute of Technology.
FRED HOLUBOW was elected a director of our company in July 1999. Mr. Holubow
has been a Vice President of Pegasus Associates, a registered investment
advisement firm since he founded Pegasus in 1982. He specializes in analyzing
and investing in pharmaceutical and biotechnology companies. Mr. Holubow
serves on the Board for ThermoRetec and has served on the Boards for
Bio-Technology General Corp. and Unimed Pharmaceuticals, Inc.
ROSS MANGANO was elected a director of our company in July 1999. Mr. Mangano
has been the President and a director of Oliver Estate, Inc., a management
company specializing in investments in public and private companies since
1971. He has been the Chairman of Cerprobe Corporation, and serves as a
director for Blue Chip Casino, Inc.; Orchard Software Corporation; Tower
Federal Savings Bank; and U.S. RealTel Inc.
EDWARD C. ROSENOW, III, M.D. has been a director of our company since
November 1997. Dr. Rosenow was the Arthur M. and Gladys D. Gray Professor of
Medicine at the Mayo Clinic from 1988 until his recent retirement. Beginning
with his residency in 1960, Dr. Rosenow has worked at the Mayo Clinic in many
professional capacities including as a Consultant in Internal Medicine
(Thoracic Diseases) from 1966 to 1996, an Assistant Professor, Associate
Professor and Professor of Medicine at the Mayo Clinic Medical School,
President of the Mayo Clinic Staff in 1986, and Chair of the Division of
Pulmonary and Critical Care Medicine from 1987 to 1994. Dr. Rosenow has also
served as a consultant to NASA, space station FREEDOM at the Johnson Space
Center in Houston, Texas from 1989 to 1990 and as the President of the
American College of Chest Physicians from 1989 to 1990. He is a Master Fellow
of the American College of Physicians as well as Master Fellow of the
American College of Chest Physicians. In 1998, he received the Mayo
Distinguished Alumnus Award.
ANGELA HO has been a director of our company since June 1998. Ms. Ho was
elected to our Board of Directors as a representative of certain major
investors in Hong Kong. Ms. Ho has been the Vice Chairman and Chief Managing
Officer of Jet Asia Ltd., a Hong Kong-based
7
<PAGE>
aircraft and management company, since April 1996. From June 1996 to June
1998, Ms. Ho was the President of Ho Galleries Ltd., a New York art gallery.
She specializes in investments in small and microcap companies.
PETER KJAER has been a director of our company since July 1999. Mr. Kjaer has
been President and Chief Executive Officer of Jet Asia Ltd., a Hong
Kong-based aircraft and management company, since April 1996 and a
representative of certain major investors in that province. From April 1989
to July 1996, Mr. Kjaer was the General Manager and a director of the Gallery
of Contemporary Living Ltd., a Hong Kong-based art gallery.
AVI BEN-ABRAHAM, M.D. founded our company and has been a director of our
company since inception. Dr. Ben-Abraham was the Chairman of your Board of
Directors and Chief Executive Officer of our company from inception to March
1998. Dr. Ben-Abraham was a trustee of the Morehouse School of Medicine in
Atlanta, Georgia until December 1998. From July 1995 to March 1998, Dr.
Ben-Abraham served as Chairman, Chief Executive Officer and Director of
Structured Biologicals, Inc., a predecessor company of BioSante.
INFORMATION ABOUT YOUR BOARD OF DIRECTORS AND ITS COMMITTEES
Your Board of Directors met three times and took action by written consent on
two occasions during fiscal 1999. All of the directors attended 75% or more
of the meetings of your Board of Directors and all such committees on which
they served during fiscal 1999.
Your Board of Directors has an Audit and Finance Committee, Compensation
Committee and Scientific Review Committee.
AUDIT AND FINANCE COMMITTEE. The Audit and Finance Committee provides
assistance to your Board of Directors in satisfying its fiduciary
responsibilities relating to our accounting, auditing, operating and
reporting practices, and reviews our annual financial statements, the
selection and work of our independent auditors and the adequacy of internal
controls for compliance with corporate policies and directives. The Audit and
Finance Committee consisted of Dr. Sullivan, Mr. Mangano and Mr. Kjaer as of
April 28, 2000. The Audit and Finance Committee met once during fiscal 1999.
COMPENSATION COMMITTEE. The Compensation Committee:
* reviews general programs of compensation and benefits for all of our
employees;
* makes recommendations to your Board of Directors concerning matters as
compensation to be paid to our officers and directors; and
* administers our stock option plan, pursuant to which stock options may be
granted to our eligible employees, officers, directors and consultants.
The Compensation Committee consisted of Dr. Sullivan, Mr. Morgenstern and Ms.
Ho as of April 28, 2000. The Compensation Committee met twice during fiscal
1999.
SCIENTIFIC REVIEW COMMITTEE. The Scientific Review Committee assists in
evaluating potential new licenses or new products. The Scientific Review
Committee consisted of Dr. Sullivan, Mr. Holubow and Dr. Rosenow as of April
28, 2000. The Scientific Review Committee did not meet during fiscal 1999.
DIRECTOR COMPENSATION
We do not pay fees to our directors. We do, however, periodically compensate
our directors through the granting of stock options. On October 28, 1999, we
granted stock options to purchase: (1) 125,000 shares of common stock to Dr.
Sullivan, (2) 75,000 shares of common stock to each of Messrs. Morgenstern,
Holubow, Mangano and Kjaer, (3) 50,000 shares of common stock to Dr. Rosenow
and (4) 25,000 shares of common stock to each of Dr. Ben-Abraham and Ms. Ho.
These options have an exercise price of $.285 per share, fully vest on
October 27, 2000 and expire five years from the date of grant.
REIMBURSEMENT OF EXPENSES. All directors are reimbursed for travel expenses
for attending meetings of your Board of Directors and any Board committees.
8
<PAGE>
EXECUTIVE COMPENSATION AND OTHER BENEFITS
------------------
SUMMARY OF CASH AND OTHER COMPENSATION
The following table provides summary information concerning cash and
non-cash compensation paid to or earned by our Chief Executive Officer and
our executive officers, all of whom received or earned cash and non-cash
salary and bonus of more than $100,000, for the fiscal year ended December
31, 1999.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
------------------------------- ----------------
SECURITIES
UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY ($) BONUS ($) OPTIONS (#) COMPENSATION ($)
- ---------------------------------------- ---- ----------- --------- ---------------- ----------------
<S> <C> <C> <C> <C> <C>
Stephen M. Simes (1).................... 1999 $250,000 $115,000 1,856,250 $21,882 (2)
PRESIDENT AND CHIEF EXECUTIVE OFFICER 1998 218,795 0 1,000,000 16,333 (2)
Claus G.J. Wagner-Bartak, D.Sc. (3).....
EXECUTIVE VICE PRESIDENT AND CHIEF 1999 159,000 (4) 0 0 0
SCIENTIFIC OFFICER 1998 105,000 0 500,000 65,000 (5)
Phillip B. Donenberg.................... 1999 110,000 15,000 521,875 13,001 (6)
CHIEF FINANCIAL OFFICER, TREASURER 1998 49,359 0 340,000 5,984 (6)
AND SECRETARY
</TABLE>
- --------------------------
(1) Mr. Simes became our President in January 1998 and Chief Executive
Officer in March 1998.
(2) Represents an auto allowance ($12,000 in 1999 and $11,333 in 1998), a
401(k) matching contribution ($5,000 in each of 1999 and 1998) and
insurance premiums and taxes associated with the premiums of $4,822
paid by BioSante in 1999.
(3) Effective February 28, 1999, Dr. Wagner-Bartak's employment with our
company terminated and his options to purchase 500,000 shares of common
stock were cancelled.
(4) A portion of Dr. Wagner-Bartak's 1999 salary ($129,000) represents
salary continuation through July 10, 1999, pursuant to a settlement
agreement as described in more detail under the heading "Employment and
Severance Agreements" on page 12.
(5) Represents amounts paid to a corporation controlled by Dr.
Wagner-Bartak ($60,000) and a 401(k) matching contribution ($5,000) to
Dr. Wagner-Bartak.
(6) Represents an auto allowance ($7,200 in 1999 and $3,484 in 1998), a
401(k) matching contribution ($5,000 in 1999 and $2,500 in 1998) and
insurance premiums paid and taxes associated with the premiums of $801
paid by BioSante in 1999.
9
<PAGE>
OPTION GRANTS IN LAST FISCAL YEAR
The following tables summarize option grants and exercises during
the fiscal year ended December 31, 1999 to or by each of the executive
officers named in the Summary Compensation Table on page 9 and the potential
realizable value of the options held by these persons at December 31, 1999.
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS (1)
------------------------------------------------------------------------
NUMBER OF PERCENT OF
SECURITIES TOTAL OPTIONS
UNDERLYING GRANTED TO EXERCISE
OPTIONS EMPLOYEES IN PRICE EXPIRATION
NAME GRANTED (#) FISCAL YEAR PER SHARE DATE
- ---- ---------------- ---------------- --------------- ---------------
<S> <C> <C> <C> <C>
Stephen M. Simes........................ 1,856,250 (2) 72.99% $0.23 03/29/04
Claus G.J. Wagner-Bartak, D.Sc.(3)...... -- -- -- --
Phillip B. Donenberg.................... 521,875 (4) 20.52% $0.23 03/29/04
</TABLE>
- ---------------------------------------------
(1) All of the options granted to the individuals in this table were
granted under our 1998 Stock Option Plan.
(2) These options are immediately exercisable with respect to 272,059
shares and become exercisable with respect to 408,088 shares on a
quarterly basis over a two-year period beginning on April 21, 1999 and
with respect to 1,176,108 shares on a quarterly basis over a three-year
period beginning on June 30, 1999, so long as Mr. Simes remains
employed by us at that date. To the extent not already exercisable,
these options become immediately exercisable in full upon certain
changes in control of our company and remain exercisable for the
remainder of their term.
(3) Dr. Wagner-Bartak's employment with our company terminated effective as
of February 28, 1999 at which time all of his options were cancelled.
(4) These options are immediately exercisable with respect to 57,251 shares
and become exercisable with respect to 171,752 shares on a quarterly
basis over a two and half year period beginning on April 1, 1999 and
with respect to 292,872 shares on a quarterly basis over a three-year
period beginning on June 30, 1999, so long as Mr. Donenberg remains
employed by us at that date. To the extent not already exercisable,
these options become immediately exercisable in full upon certain
changes in control of our company and remain exercisable for the
remainder of their term.
10
<PAGE>
AGGREGATED OPTION EXERCISES IN LAST FISCAL
YEAR AND FISCAL YEAR-END OPTION VALUES
The following table summarizes the number and value of options
exercised during 1999 and the value of options held by each of the executive
officers named in the Summary Compensation Table on page 9 at December 31,
1999. None of our executive officers exercised any stock options during 1999.
<TABLE>
<CAPTION>
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS
OPTIONS AT DECEMBER 31, 1999 AT DECEMBER 31, 1999 (1)
---------------------------- ------------------------
NAME EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ---- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Stephen M. Simes........................ 1,344,119 1,512,131 $300,863 $357,199
Dr. Claus Wagner-Bartak (2)............. -- -- -- --
Phillip B. Donenberg.................... 360,669 501,206 $ 82,092 $116,377
</TABLE>
- --------------------------
(1) Value based on the difference between the fair market value of one
share of our common stock at December 31, 1999 (U.S. $0.48), the
closing sale price on that date as reported by the Canadian Venture
Exchange, converted to U.S. dollars per OANDA currency converter at a
conversion rate of U.S. $1.00 to Cdn. $1.4529, and the exercise price
of the options ranging from $0.23 to $0.29 per share. Options are
in-the-money if the market price of the shares exceeds the option
exercise price.
(2) Dr. Wagner-Bartak's employment with our company terminated effective as
of February 28, 1999, at which time all of his options were cancelled.
EMPLOYMENT AND SEVERANCE AGREEMENTS
SIMES EMPLOYMENT AGREEMENT
In January 1998, we entered into a letter agreement with Stephen M. Simes
pursuant to which Mr. Simes serves as our President, Chief Executive Officer
and Executive Vice Chairman. The initial term of this agreement continues
until December 31, 2000, after which time the term will be automatically
extended for three additional years unless on or before October 1 immediately
preceding the extension, either party gives written notice to the other of
the termination of the agreement.
Mr. Simes' base salary is $250,000 per year, and he is entitled to receive an
annual performance bonus of up to 50% of his then base salary if certain
performance criteria are met. Under the terms of this agreement, Mr. Simes
was granted a five-year option to purchase 600,000 shares of common stock at
an exercise price of $0.29 per share. This option is immediately exercisable
with respect to 100,000 shares and will become exercisable with respect to
the remaining 500,000 shares in 12 equal quarterly installments over the
initial three-year term of the agreement. Mr. Simes was also granted an
option to purchase an additional 400,000 shares of common stock at an
exercise price of $0.28 per share. This option is immediately exercisable
with respect to 33,333 shares and is exercisable with respect to the
remaining 366,667 shares in 12 equal quarterly installments over the initial
three-year term of the agreement. If Mr. Simes is terminated without cause or
upon a change in control or if he terminates his employment for good reason,
all of his options will become immediately exercisable and will remain
exercisable for a period of one year (for the remainder of their term in the
event of a change in control), and he will be entitled to a minimum severance
payment of 12 months base salary. Mr. Simes is also subject to assignment of
inventions, confidentiality and non-competition provisions.
This agreement was amended in connection with our May 1999 private placement
to clarify that the anti-dilution rights held by Mr. Simes apply only in the
context of a stock dividend, stock split or exchange or other similar change
in capital and to waive any rights Mr. Simes may
11
<PAGE>
have had under the agreement if the May 1999 private placement would have
resulted in a change in control of our company, including the acceleration of
the exercisability of his stock options. In connection with the amendment, we
granted Mr. Simes an option to purchase 5% of the number of shares of common
stock sold in the May 1999 private placement (excluding any shares issuable
pursuant to the warrants).
DONENBERG EMPLOYMENT AGREEMENT
In June 1998, we entered into a letter agreement with Phillip B. Donenberg
pursuant to which Mr. Donenberg serves our Chief Financial Officer. The term
of this agreement continues until either party gives 30 days written notice
to the other of the termination of the agreement.
Mr. Donenberg's base salary is $110,000 per year, and he is entitled to
receive an annual performance bonus of up to 30% of his then base salary if
certain performance criteria are met. Under the terms of this agreement, Mr.
Donenberg was granted a five-year option to purchase 340,000 shares of common
stock at an exercise price of $0.28 per share. This option is immediately
exercisable with respect to 34,000 shares and is exercisable with respect to
the remaining 306,000 shares in 12 equal quarterly installments with the
first installment vesting on October 1, 1998. If Mr. Donenberg is terminated
without cause or upon a change in control or if he terminates his employment
for good reason, all of his options will become immediately exercisable and
will remain exercisable for a period of one year (for the remainder of their
term in the event of a change in control), and he will be entitled to a
minimum severance payment of 12 months base salary. Mr. Donenberg is also
subject to assignment of inventions, confidentiality and non-competition
provisions.
This agreement was amended in connection with our May 1999 private placement
to clarify that the anti-dilution rights held by Mr. Donenberg apply only in
the context of a stock dividend, stock split or exchange or other similar
change in capital and to waive any rights Mr. Donenberg may have had under
the agreement if the May 1999 private placement would have resulted in a
change in control of our company, including the acceleration of the
exercisability of his stock options. In connection with the amendment, we
granted Mr. Donenberg an option to purchase 1.5% of the number of shares of
common stock sold in the May 1999 private placement (excluding any shares
issuable pursuant to the warrants).
WAGNER-BARTAK SEVERANCE AGREEMENT
In February 1999, we entered into a severance agreement with Claus G.J.
Wagner-Bartak, the former Executive Vice-President and Chief Scientific
Officer and a director. Under this agreement, we agreed to provide Dr.
Wagner-Bartak with certain payments and benefits, including (1) a one-time
lump sum payment of $129,000 on March 10, 1999 (representing $180,000 of pay
as severance, less $51,000 as repayment of an amount owing to BioSante by Dr.
Wagner-Bartak, and (3) payment of premiums on Dr. Wagner-Bartak's medical
insurance plan until February 28, 2000. Under this separation agreement, Dr.
Wagner-Bartak agreed (1) to terminate his right to exercise his outstanding
stock options and (2) to not stand for re-election as a director at our next
annual meeting. BioSante and Dr. Wagner-Bartak have mutually agreed to
release each other from any and all actions, claims, suits, damages or
judgements.
CHANGE IN CONTROL ARRANGEMENTS
Our 1998 Stock Option Plan contains provisions under which the options
granted under that plan would become fully exercisable following certain
changes in control of our company, such as:
* the sale, lease, exchange or other transfer of all or substantially all of
the assets of our company to a corporation that is not controlled by us;
* the approval by our shareholders of any plan or proposal for the
liquidation or dissolution of our company;
12
<PAGE>
* certain merger or business combination transactions;
* more than 50% of our outstanding voting shares are acquired by any person
or group of persons who did not own any shares of common stock on the
effective date of the plan; and
* certain changes in the composition of our Board of Directors.
RELATED PARTY RELATIONSHIPS AND TRANSACTIONS
-------------------------
DIRECTOR RELATIONSHIPS
Messrs. Morgenstern, Holubow and Mangano were elected to our Board of
Directors in July 1999 as representatives of the new lead investors in the
May 1999 private placement. We refer you to the discussion under the heading
"May 1999 Private Placement" below.
Angela Ho, a director of our company, owns approximately 3.0% of our
outstanding voting securities and was elected to our Board of Directors as a
representative of our several investors located in Hong Kong. Ms. Ho has not
entered into any voting agreements with these Hong Kong investors nor does
she otherwise have any control over the voting of shares held by these
investors.
Mr. Kjaer was elected to our Board of Directors as a representative of our
Hong Kong investors in July 1999. Mr. Kjaer has not entered into any voting
agreements with these Hong Kong investors nor does he otherwise have any
control over the voting of shares held by these investors.
MAY 1999 PRIVATE PLACEMENT
In connection with our May 1999 private placement, we entered into a
Shareholders' Agreement with the investors, which included Stephen M. Simes,
Victor Morgenstern, an affiliated trust and a partnership, Fred Holubow, JO &
Co., of which Ross Mangano is President, and certain of our major investors
located in Hong Kong, including Hans Michael Jebsen, Marcus Jebsen and King
Cho Fung. This agreement contains, among other things, a voting agreement
with respect to the election of directors and a lock-up agreement under which
they have agreed that they will not offer, sell or otherwise dispose of any
shares until September 2000.
13
<PAGE>
PROPOSAL TO AMEND OUR 1998 STOCK OPTION PLAN TO INCREASE
THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE
(PROPOSAL 2)
--------------
PROPOSED AMENDMENT
On December 8, 1998, your Board of Directors adopted our 1998 Stock Option
Plan, and on July 13, 1999 our shareholders approved the option plan. This
option plan provides for the grant to employees, officers, directors,
consultants and independent contractors of our company of options to purchase
shares of common stock that qualify as "incentive stock options" within the
meaning of Section 422 of the Internal Revenue Code of 1986, as amended, as
well as non-statutory options that do not qualify as incentive stock options.
This plan is administered by the Compensation Committee of our Board of
Directors, which determines the persons who are to receive awards, as well as
the type, terms and number of shares subject to each award.
On March 14, 2000, your Board of Directors amended the option plan, subject
to shareholder approval, to increase the number of shares of common stock
reserved for issuance under the option plan by 2,000,000 shares, from
5,000,000 shares to 7,000,000 shares. You are being asked to approve this
amendment at the Annual and Special Meeting.
PURPOSE OF THE AMENDMENT
Providing stock option grants under our option plan is an important element
in our overall success. In general, your Board of Directors believes that
equity-based incentives align the interests of our management and employees
with those of our shareholders. In addition, providing stock option grants
under the option plan is an important strategy for attracting and retaining
the type of high-quality executives, employees and advisors our Board of
Directors believes is necessary for the achievement of our goals.
Given the intense competition for such personnel, your Board of Directors
believes that its ability to offer competitive compensation packages,
including those with equity-based incentive components, is particularly
important in attracting and retaining qualified candidates.
SUMMARY OF THE 1998 STOCK OPTION PLAN
A general description of the basic features of our option plan is outlined
below. Unless otherwise indicated, the following summary of the principal
provisions of the plan assumes the approval of the proposed amendment
increasing the number of shares of common stock reserved for issuance. This
summary is qualified in its entirety by reference to the actual text of the
option plan, a copy of which you may obtain from us at the address set forth
at the beginning of this proxy statement.
PURPOSE OF THE PLAN. The option plan's purpose is to advance our interests
and the interests of our shareholders by enabling us to attract and retain
talented persons by providing an incentive to these individuals through
equity participation in BioSante and also rewarding individuals who
contribute to the achievement of our economic objectives.
ELIGIBLE PARTICIPANTS. All employees of BioSante and any non-employee
directors, consultants and independent contractors of BioSante who, in the
judgment of the Compensation Committee, have contributed, are contributing or
are expected to contribute to the achievement of our economic objectives are
eligible to participate in the option plan. On March 31, 2000, approximately
14 individuals were eligible to receive options under the option plan.
14
<PAGE>
Participants may be granted one or more options. The options will always be
subject to whatever terms and conditions the Compensation Committee
determines, provided such terms and conditions are consistent with the option
plan. All options are deemed granted as of the date specified in the
Compensation Committee's resolution, which will be the date of the
participant's option agreement.
Pursuant to the rules of the Canadian Venture Exchange, the number of shares
reserved for issuance to any one person, pursuant to option grants, must not
exceed 5% of the Outstanding Issued (the number of shares outstanding on a
non-diluted basis).
ADMINISTRATION. The Compensation Committee of your Board of Directors
administers the option plan. The Compensation Committee has the authority to
determine all provisions of options as long as they are consistent with the
terms of the option plan. The Compensation Committee also has the authority
to amend or modify the terms of any outstanding options in any manner. Any
amendment or modification, however, must be permitted by the option plan and
may not adversely affect any participant's rights without his or her consent.
Each determination, interpretation or other action of the Compensation
Committee will be conclusive and binding for all purposes on all persons.
STOCK SUBJECT TO THE OPTION PLAN. The amendment to the option plan proposed
hereby would increase the number of shares specifically reserved for issuance
under the option plan from 5,000,000 to 7,000,000 shares.
As of March 31, 2000, no shares of common stock had been issued upon the
exercise of options granted under the option plan, and options to purchase
4,973,125 shares of common stock were outstanding. Accordingly, 26,875 shares
remained available for future grant under the option plan as of that date.
Assuming approval of an increase of 2,000,000 shares to the option plan,
2,026,875 shares would be available for future grants.
The following points describe how our Compensation Committee determines the
number of shares of common stock available for issuance under our option plan
at any point in time.
* OUTSTANDING OPTIONS -- reduces the maximum number of shares available for
issuance.
* SHARES ISSUED UPON EXERCISE OF OUTSTANDING OPTIONS -- reduces the maximum
number of shares available for issuance.
* OPTION TERMINATES UNEXERCISED OR UNVESTED -- shares become available again
for issuance.
* WE PAY FOR THE OPTIONS, IN CASH, NOT COMMON STOCK -- shares become
available again for issuance.
In the event of any reorganization, merger, recapitalization, stock dividend,
stock split or similar change in our corporate structure or our shares,
appropriate adjustments will be made to the number and kind of shares
reserved under the plan and under outstanding options and to the exercise
price of outstanding options.
OPTIONS. An option provides the optionee with the opportunity to purchase a
specified number of shares of common stock at a predetermined price for a
specific period of time. Incentive options must be granted with an exercise
price equal to at least the fair market value of the common stock on the date
of grant. Non-qualified options must be granted with an exercise price equal
to at least 85% of the fair market value of the common stock on the date of
grant. For purposes of the plan, the fair market value of the common stock is
the closing price as reported by the Nasdaq SmallCap Market, OTC Bulletin
Board or the National Quotation Bureau, Inc. On March 31, 2000, the closing
sale price of a share of our common stock on the National Quotation Bureau,
Inc. was $0.69.
Options will become exercisable at such times and in such installments as may
be determined by the Compensation Committee, provided that options may not be
exercisable after 10 years from their date of grant.
15
<PAGE>
The exercise price of options must be paid in cash, except that the
Compensation Committee may allow payment to be made (in whole or in part) by
tender of a "broker exercise notice" (pursuant to which the broker or dealer
is instructed to sell enough shares or loan the optionee enough money to pay
the exercise price and to remit such sums to us), a promissory note, a
transfer of shares of common stock (either previously owned by the
participant or to be acquired upon option exercise), or by a combination of
such methods. The aggregate fair market value of shares of common stock with
respect to which incentive stock options may become exercisable for the first
time by a participant in any calendar year may not exceed $100,000. Any
incentive options in excess of this amount will be treated as non-statutory
options.
EFFECT OF CHANGE IN CONTROL. We refer you to "Executive Compensation and
Other Benefits -- Change in Control Arrangements" for discussion regarding
the effects of a "change in control" on options granted under the option plan.
EFFECT OF TERMINATION OF EMPLOYMENT ON SERVICE. If a participant's employment
or other service with BioSante terminates by reason of death or disability,
all outstanding options will remain exercisable to the extent then
exercisable for a period of six months after termination, but in no event
after their original expiration date. If a participant's employment or other
service with BioSante is terminated by reason of retirement, all outstanding
options will remain exercisable to the extent then exercisable for a period
of three months after termination, but in no event after their original
expiration date.
If a participant's employment or other service with us is terminated for any
other reason, other than for cause, all outstanding options will remain
exercisable to the extent then exercisable for a period of three months after
termination.
If a participant's employment or other service with us is terminated for
cause, all outstanding options will immediately terminate without notice.
The Board of Directors may, in our discretion, modify these post-termination
provisions, provided that no option may remain exercisable beyond its
expiration date.
AMENDMENT OF OPTION PLAN. Your Board of Directors may suspend or terminate
the option plan or any portion thereof at any time, and may amend the option
plan from time to time to conform the plan to any change in applicable laws
or regulations or in any other respect your Board of Directors may deem to be
in the best interests of BioSante.
Your Board of Directors may not, however, make an amendment to the option
plan without shareholder approval if shareholder approval is required under
Rule 16(b)(3) under the Securities Exchange Act of 1934, Section 422 of the
Internal Revenue Code or the rules of any exchange of Nasdaq or similar
regulatory body. Furthermore, your Board of Directors cannot make any
modification to the option plan that would adversely affect outstanding
options without the consent of the affected participants.
TERMINATION. The option plan will terminate at midnight on December 8, 2008,
unless terminated earlier by your Board of Directors. No options may be
granted after such termination. Options outstanding upon termination of the
option plan may continue to be exercised according to their terms.
FEDERAL INCOME TAX CONSEQUENCES
The following description of federal income tax consequences is based on
current statutes, regulations and interpretations. The description does not
include foreign, state or local income tax consequences. In addition, the
description is not intended to address specific tax consequences applicable
to directors, executive officers or greater than 10% shareholders of BioSante
or to any individual participant who receives an option under the option plan.
INCENTIVE STOCK OPTIONS. There will not be any federal income tax
consequences to either the participant or BioSante as a result of the grant
to an employee of an incentive stock option under the option plan. The
exercise by a participant of
16
<PAGE>
an incentive stock option also will not result in any federal income tax
consequences to BioSante or the participant, except that:
* an amount equal to the excess of the fair market value of the shares
acquired upon exercise of the incentive stock option, determined at the
time of exercise, over the amount paid for the shares by the participant
will be includable in the participant's alternative minimum taxable income
for purposes of the alternative minimum tax, and
* the participant may be subject to an additional excise tax if any amounts
are treated as excess parachute payments, as discussed below.
Special rules will apply if previously acquired shares of common stock are
permitted to be tendered in payment of an option exercise price.
When a participant disposes of shares acquired upon exercise of an incentive
stock option, the federal income tax consequences will depend upon how long
the participant held those shares. If the participant does not dispose of the
shares within two years after the incentive stock option was granted, nor
within one year after the participant exercised the incentive stock option,
then the participant will recognize a long-term capital gain or loss. The
amount of the long-term capital gain or loss will be equal to the difference
between:
* the amount the participant realized on disposition of the shares, and
* the option price at which the participant acquired the shares.
We are not entitled to any compensation expense deduction under these
circumstances.
If the participant does not satisfy both of the above holding period
requirements, then the participant will be required to report as ordinary
income, in the year the participant disposes of the shares, the amount by
which the lesser of:
* the fair market value of the shares at the time of exercise of the
incentive stock option, or
* the amount realized on the disposition of the shares, exceeds the option
price for the shares.
We will be entitled to a compensation expense deduction in an amount equal to
the ordinary income includable in the taxable income of the participant. This
compensation income may be subject to withholding. The remainder of the gain
recognized on the disposition, if any, or any loss recognized on the
disposition, will be treated as long-term or short-term capital gain or loss,
depending on the holding period.
NON-STATUTORY STOCK OPTIONS. Neither the participant nor BioSante incurs any
federal income tax consequences as a result of the grant of a non-statutory
stock option. Upon exercise of a non-statutory stock option, a participant
will recognize ordinary income, subject to withholding, on the date of
exercise in an amount equal to the difference between:
* the fair market value of the shares purchased, determined on the date of
exercise, and
* the consideration paid for the shares.
The participant may be subject to an additional excise tax if any amounts are
treated as excess parachute payments (see explanation below). Special rules
will apply if previously acquired shares of common stock are permitted to be
tendered in payment of an option exercise price.
At the time of a subsequent sale or disposition of any shares of common stock
obtained upon exercise of a non-statutory stock option, any gain or loss will
be treated as long-term or short-term capital gain or loss, depending on the
holding period from the date of exercise.
In general, we will be entitled to a compensation expense deduction in
connection with the exercise of a non-statutory stock option for any amounts
includable in the taxable income of the participant as ordinary income,
provided we
17
<PAGE>
comply with any applicable withholding requirements.
EXCISE TAX ON PARACHUTE PAYMENTS. The Internal Revenue Code also imposes a
20% excise tax on the recipient of "excess parachute payments," as defined in
the Internal Revenue Code and denies tax deductibility to us on excess
parachute payments. Generally, parachute payments are payments in the nature
of compensation to employees of a company who are officers, shareholders or
highly compensated individuals, which payments are contingent upon a change
in ownership or effective control of the company, or in the ownership of a
substantial portion of the assets of the company. For example, acceleration
of the exercisability of options or the vesting of restricted stock awards
upon a change in control of BioSante may constitute parachute payments, and
in certain cases, "excess parachute payments."
SECTION 162(m). Under Section 162(m) of the Internal Revenue Code, the
deductibility of certain compensation paid to the chief executive officer and
each of the four other most highly compensated executives of a publicly held
corporation is limited to $1,000,000. Compensation for this purpose generally
includes any items of compensation expense described above in connection with
incentive awards under the option plan. However, certain types of
compensation are excepted from this limit, including compensation that
qualifies as "performance-based compensation." Under Section 162(m), any
compensation expense resulting from the exercise of options under the option
plan with exercise prices equal to (or greater than) the fair market value of
the common stock on the date of grant should qualify as "performance-based
compensation" excepted from the limit of Section 162(m). However,
compensation expense in connection with any other incentive awards under the
option plan will be subject to this limit.
OPTIONS UNDER THE OPTION PLAN
The table below summarizes outstanding options under our option plan as of
March 31, 2000. The options granted in fiscal 1999 to the Named Executive
Officers are also disclosed in the Summary of Compensation Table on page 9
and the Option Grants in Last Fiscal Year on page 10, as required by the
rules of the Securities and Exchange Commission.
NEW PLAN BENEFITS
1998 STOCK OPTION PLAN
<TABLE>
<CAPTION>
NUMBER
OF SHARES
UNDERLYING
NAME AND POSITION OPTIONS
- ----------------------------------- ------------
<S> <C>
Stephen M. Simes....................... 2,856,250
Phillip B. Donenberg................... 861,875
Claus G.J. Wagner-Bartak............... --
Executive Group........................ 3,718,125
Non-Executive Director Group........... 925,000
Non-Executive Officer Employee Group... 330,000
----------
Total......................... 4,973,125
</TABLE>
VOTE REQUIRED
The affirmative vote of the holders of a majority of the shares of our common
stock and class C stock, present in person or by proxy on this matter at the
Annual and Special Meeting, voting together as a single class, is necessary
for approval of the amendment to our option plan to increase the number of
shares of common stock reserved for issuance by 2,000,000 shares, from
5,000,000 shares to 7,000,000 shares.
BOARD RECOMMENDATION
Your Board of Directors recommends that you vote FOR approval of the
amendment to our option plan to increase the number of shares of common stock
reserved for issuance by 2,000,000, from 5,000,000 shares to 7,000,000
shares. Unless a contrary choice is specified, proxies solicited by the Board
will be voted FOR approval of the amendment to our option plan.
18
<PAGE>
RATIFICATION OF SELECTION OF
INDEPENDENT AUDITORS
(PROPOSAL 3)
-----------------------
APPOINTMENT OF AUDITORS
Your Board of Directors has appointed Deloitte & Touche L.L.P. as our
independent auditors for the year ending December 31, 2000. Deloitte & Touche
L.L.P. has acted as our independent auditors since January 1, 1999. Prior to
that date, Deloitte & Touche, C.A. in Canada acted as our independent
auditors since our inception in August 1996.
Although it is not required to do so, your Board of Directors wishes to
submit the selection of Deloitte & Touche L.L.P. to the shareholders for
ratification. If you do not ratify the appointment of Deloitte & Touche
L.L.P., another firm of independent auditors will be considered by your Board
of Directors.
Representatives of Deloitte & Touche L.L.P. will be present at the Annual and
Special Meeting via telephone, will have an opportunity to make a statement
if they so desire and will be available to respond to appropriate questions.
VOTE REQUIRED
The affirmative vote of the holders of a majority of the shares of our common
stock and class C stock, present in person or by proxy on this matter at the
Annual and Special Meeting, voting together as a single class, is necessary
for the ratification of Deloitte & Touche L.L.P., as our independent auditors
for the year ending December 31, 2000.
BOARD RECOMMENDATION
Your Board of Directors recommends a vote FOR ratification of the appointment
of Deloitte & Touche L.L.P. as our independent auditors for the year ending
December 31, 2000. Unless a contrary choice is specified, proxies solicited
by the Board will be voted FOR the ratification of Deloitte & Touche L.L.P.
19
<PAGE>
OTHER MATTERS
-------------------------------
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires our directors
and executive officers and all persons who beneficially own more than 10% of
the outstanding shares of our common stock to file with the Securities and
Exchange Commission initial reports of ownership and reports of changes in
ownership of our common stock.
Executive officers, directors and greater than 10% beneficial owners are also
required to furnish us with copies of all Section 16(a) forms they file.
None of our directors, executive officers and beneficial owners of greater
than 10% of our common stock were required to file forms under Section 16 of
the Securities Exchange Act of 1934 during the fiscal year ended December 31,
1999.
SHAREHOLDER PROPOSALS FOR 2001 ANNUAL MEETING
Shareholder proposals intended to be presented in the proxy materials
relating to the next Annual Meeting of Shareholders must be received by us on
or before August 28, 2000 and must satisfy the requirements of the proxy
rules promulgated by the Securities and Exchange Commission.
A shareholder who wishes to make a proposal at the next Annual Meeting
without including the proposal in our proxy statement must notify us by June
14, 2000. If a shareholder fails to give notice by this date, then the
persons named as proxies in the proxies solicited by us for the next Annual
Meeting will have discretionary authority to vote on the proposal.
OTHER BUSINESS
Our management does not intend to present other items of business and knows
of no items of business that are likely to be brought before the Annual and
Special Meeting, except those described in this proxy statement. However, if
any other matters should properly come before the Annual and Special Meeting,
the persons named in the enclosed proxy will have discretionary authority to
vote such proxy in accordance with their best judgment on the matters.
COPIES OF 2000 ANNUAL REPORT
WE HAVE SENT TO EACH OF OUR SHAREHOLDERS A COPY OF OUR ANNUAL REPORT ON FORM
10-KSB (WITHOUT EXHIBITS) FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999. We
will furnish a copy of any exhibit to our Form 10-KSB upon receipt from any
such person of a written request for such exhibits upon the payment of our
reasonable expenses in furnishing the exhibits.
This request should be sent to:
BioSante Pharmaceuticals, Inc.
175 Olde Half Day Road
Lincolnshire, Illinois 60069
Attn: Shareholder Information
20
<PAGE>
-------------------------
Your vote is important. Whether or not you plan to attend the Annual and
Special Meeting, please vote your shares of common stock and class C stock by
marking, signing, dating and promptly returning the enclosed proxy card in
the envelope provided. No postage is required for mailing in the United
States or from Canada.
By Order of the Board of Directors
/s/ Stephen M. Simes
Stephen M. Simes
PRESIDENT AND CHIEF EXECUTIVE OFFICER
May 1, 2000
Lincolnshire, Illinois
21
<PAGE>
STOCK OPTION PLAN
PART I - INTRODUCTION
1.01 PURPOSE
The purpose of the Plan is to secure for BEN-ABRAHAM TECHNOLOGIES INC. (the
"Company") and its shareholders the benefits of incentive inherent in share
ownership by the directors, senior officers and key employees of the Company and
its Affiliates who, in the judgment of the Board, will be largely responsible
for its future growth and success.
1.02 DEFINITIONS
(a) "AFFILIATE" has the meaning ascribed thereto in the BUSINESS
CORPORATIONS ACT, (Ontario) as amended from time to time.
(b) "BOARD" means the board of directors of the Company.
(c) "COMPANY" means Ben-Abraham Technologies Inc., a corporation
incorporated under the laws of Wyoming.
(d) "ELIGIBLE PERSON" shall mean a senior officer or director of the
Company or of an Affiliate of the Company ("Executive") or an employee of
the Company or an Affiliate of the Company ("Employee") or a personal
holding company controlled by an Executive or an Employee or a Registered
Retirement Savings Plan established by an Executive or an Employee. In the
event that a personal holding company ceases to be controlled by an
Executive or an Employee, any options granted to such personal holding
company shall forthwith be terminated.
(e) "INSIDER" means;
(i) an insider as defined in the Securities Act (Ontario), other than
a person who falls within the definition solely by virtue of being a
director or senior officer of a subsidiary of the Company; and
(ii) an associate of any person who is an insider by virtue of the
preceding sub-clause (i).
(f) "MARKET PRICE" at any date in respect of the Shares means the closing
sale price of such Shares on a stock exchange in Canada on which the Shares
are listed and posted for trading, as may be selected for such purpose by
the Board, on the trading day immediately preceding such date; provided
that if the Shares are listed on more than one Stock Exchange, then the
Market Price shall be the closing sale price of such Shares on the Stock
Exchange on which the greatest volume of Shares traded on such trading day.
In the event that such Shares are not listed and posted for trading on any
stock exchange
<PAGE>
in Canada, the Market Price shall be the fair value of such Shares as
determined by the Board in its sole discretion.
(g) "OPTION" shall mean an option granted under the terms of the Share
Option Plan.
(h) "OPTION PERIOD" shall mean the period during which an option may be
exercised.
(i) "OPTIONEE" shall mean an Eligible Person to whom an Option has been
granted under the terms of the Share Option Plan.
(j) "OUTSTANDING ISSUE" means the number of shares of the applicable class
outstanding on a non-diluted basis.
(k) "PARTICIPANT" means, in respect of the Plan, an Eligible Person who is
eligible and elects to participate in the Plan.
(l) "PLAN" means, the Share Option Plan and the term "Plan" means such
plan.
(m) "SHARE OPTION PLAN" means the Plan established and operated pursuant
to Part 2 hereof.
(n) "SHARES" shall mean the Subordinate Voting Shares of the Company.
PART 2 - SHARE OPTION PLAN
2.01 PARTICIPATION
Options shall be granted only to Eligible Persons.
2.02 DETERMINATION OF OPTION RECIPIENTS
The Board shall make all necessary or desirable determinations regarding
the granting of Options to Eligible Persons and may take into consideration the
present and potential contributions of a particular Eligible Person to the
success of the Company and any other factors which it may deem proper and
relevant.
2.03 PRICE
The exercise price per Share when Options are granted shall be determined
from time to time by the Board but, in any event, shall not be lower than the
Market Price.
2.04 GRANT OF OPTIONS
The Board may at any time authorize the granting of Options to such
Eligible Persons as it may select for the number of Shares that it shall
designate, subject to the provisions of the Share Option Plan. The Date of each
grant of Options shall be determined by the Board when the grant is authorized.
2
<PAGE>
Each option granted to an Eligible Person shall be evidenced by a stock
option agreement with terms and conditions consistent with the Plan and as
approved by the Board (which terms and conditions need not be the same in each
case and may be changed from time to time).
A director of the Company to whom an Option may be granted shall not
participate in the decision of the Board to grant such Option.
2.05 TERM OF OPTIONS
The Option Period shall be for not more than ten years from the date such
Option is granted, but may be reduced with respect to any such Option as
provided in section 2.8 hereof covering termination of employment or death of
the Optionee.
Except as set forth in section 2.8, no Option may be exercised unless the
Optionee is at the time of such exercise:
(a) in the case of an Employee, in the employ of the Company or any
Affiliate and shall have been continuously so employed since the grant of
his or her Option, but absence on leave, having the approval of the Company
or such Affiliate, shall not be considered an interruption of employment
for any purpose of the Share Option Plan; or
(b) in the case of an Executive, a director or senior officer of the
Company or an Affiliate and shall have been such a director or senior
officer continuously since the grant of his or her Option.
The exercise of any Option will be contingent upon receipt by the Company
of cash payment of the full purchase price of the Shares being purchased. No
Optionee or his or her legal representative, legatees or distributees will be,
or will be deemed to be, a holder of any Shares subject to an Option, unless and
until certificates for such Shares are issued to him, her or them under the
terms of the Share Option Plan.
2.06 RESTRICTIONS ON GRANT OF OPTIONS.
The granting of Options shall be subject to the following conditions:
(c) not more than 10% of the Outstanding Issue may be reserved for the
granting of Options in any one-year period;
(d) not more than 10% of the Outstanding Issue may be reserved for the
grant of Options to insiders within a one-year period;
(e) within a one year period, not more than 10% of the Outstanding Issue
may be issued to insiders including Shares which may be issued under the
Options or which may be issued with respect to all other compensation
granted by the Company to such insider;
3
<PAGE>
(f) note more than 5% of the Outstanding Issue may be reserved for the
granting of Options to any one insider in any one-year period; and
(g) not more than 5 % of the Outstanding Issue may be issued to any one
insider in a one-year period.
2.07 LAPSED OPTIONS
If Options are surrendered, terminated or expire without being exercised in
whole or in part, new Options may be granted covering the Shares not purchased
under such lapsed Options.
2.08 EFFECT OF TERMINATION OF EMPLOYMENT OR DEATH
(h) If an Optionee shall die while employed by the Company or its
Affiliate, or while a director or senior officer of the Company or its
Affiliate, any Option held by the Optionee at the date of death shall
become exercisable, in whole or in part, but only by the person or persons
to whom the Optionee's rights under the Option shall pass by the Optionee's
will or the laws of descent and distribution. All such Options shall be
exercisable only to the extent that the Optionee was entitled to exercise
the Option at the date of his or her death and only for six months after
the date of death or prior to the expiration of the Option Period in
respect thereof, whichever is sooner.
(i) If the tenure of a director or senior officer or the employment of an
employee of the Company or its Affiliate is terminated ("Termination"), for
cause no Option held by such Optionee may be exercised following the date
upon which Termination occurred. If Termination occurs for any reason
other than cause, then any Option held by such Optionee shall be
exercisable, in whole or in part, for a period of six months after such
Termination or prior to the expiration of the Option Period in respect
thereof, whichever is sooner, or such shorter period of time as may be
determined by the Board when the Option is granted.
2.09 EFFECT OF AMALGAMATION, CONSOLIDATION OF MERGER
If the Company amalgamates, consolidates with or merges with or into
another corporation any Shares receivable on the exercise of an Option shall be
converted into the securities, property or cash which the Participant would have
received upon such amalgamation, consolidation or merger if the Participant had
exercised his or her option immediately prior to the record date applicable to
such amalgamation, consolidation or merger, and the option price shall be
adjusted appropriately by the Board and such adjustment shall be binding for all
purposes of the Share Option Plan.
2.10 ADJUSTMENT IN SHARES SUBJECT TO THE PLAN
If there is any change in the Shares through or by means of a declaration
of stock dividends of Shares or consolidations, subdivisions or
reclassifications of Shares, or otherwise, the number of Shares available under
the Share Option Plan, the Shares subject to any Option,
4
<PAGE>
and the purchase price thereof shall be adjusted appropriately by the Board and
such adjustment shall be effective and binding for all purposes of the Share
Option Plan.
PART 3 - GENERAL
3.01 NUMBER OF SHARES
The aggregate number of Shares that may be reserved for issuance under the
Plan, together with the aggregate number of Shares which are reserved for
issuance under options previously granted, shall not exceed 7,000,000 Shares.
3.02 TRANSFERABILITY
All benefits, rights and options accruing to any Participant in accordance
with the terms and conditions of the Plan shall not be transferable unless
specifically provided herein. During the lifetime of a Participant, all
benefits, rights and options may only be exercised by the Participant.
3.03 EMPLOYMENT
Nothing contained in any Plan shall confer upon any Participant any right
with respect to employment or continuance of employment with the Company or any
Affiliate, or interfere in any way with the right of the Company or any
Affiliate to terminate the Participant's employment at any time. Participation
in any Plan by a Participant is voluntary.
3.04 APPROVAL OF PLAN
The Plan shall only become effective after it has been approved by a
majority of the votes cast at a meeting of the Company's shareholders called for
such purpose; provided, however, nothing contained herein shall in any way
affect stock options previously granted by the Company and currently outstanding
or the plan (the "Former Plan") pursuant to which any of such options may have
been granted. No further options shall be granted under the Former Plan which
shall be replaced and superseded by the Plan when same is duly approved by
shareholders of the Company.
The obligation of the Company to sell and deliver Shares in accordance with
the Plan is subject to the approval of any governmental authority having
jurisdiction or any stock exchanges on which the Shares are listed for trading
which may be required in connection with the authorization, issuance or sale of
such Shares by the Company. If an Shares cannot be issued to any Participant
for any reason including, without limitation, the failure to obtain such
approval, then the obligation of the Company to issue such Shares shall
terminate and any Participant's option price paid to the Company shall be
returned to the Participant.
5
<PAGE>
3.05 ADMINISTRATION OF THE PLAN
The Board is authorized to interpret each Plan from time to time and to
adopt, amend and rescind rules and regulations for carrying out such Plan. The
interpretation and construction of any provision of any Plan by the Board shall
be final and conclusive. Administration of the Plan shall be the responsibility
of the appropriate officers of the Company and all costs in respect thereof
shall be paid by the Company.
3.06 INCOME TAXES
As a condition of and prior to participation in the Plan, a Participant
shall authorize the Company in written form to withhold from any remuneration
otherwise payable to such Participant any amounts required by any taxing
authority to be withheld for taxes of any kind as a consequence of such
participation in the Plan.
3.07 AMENDMENTS TO PLAN
The Board reserves the right to amend, modify or terminate any Plan at any
time if and when it is advisable in the absolute discretion of the Board.
However, any amendment of such Plan which could at any time:
(a) materially increase the benefits under such Plan; or
(b) result in an increase in the number of Shares which would be issued
under such Plan (except any increase resulting automatically from an
increase in the number of issued and outstanding Shares); or
(c) materially modify the requirement as to eligibility for participation
in such Plan;
shall be effective only upon the approval of the shareholders of the Company.
Any amendment to any provision of such Plan shall be subject to approval, if
required, by any regulatory body having jurisdiction over the securities of the
Company.
3.08 REPRESENTATION OR WARRANTY
The Company makes no representation or warranty as the future market value
of any Shares issued in accordance with the provision of any Plan.
3.09 INTERPRETATION
The Plan will be governed by and construed in accordance with the laws of
the Province of Ontario and the laws of Canada applicable therein.
6
<PAGE>
3.10 COMPLIANCE WITH APPLICABLE LAW, ETC.
If any provision of any Plan of any agreement entered into pursuant to any
Plan contravenes any law or an order, policy, by-law or regulation of any
regulatory body or stock exchange having authority over the Company or the Plan
then such provision shall be deemed to be amended to the extent required to
bring such provision into compliance therewith.
<PAGE>
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ITEMS 1, 2 and 3.
1. ELECTION OF DIRECTORS 01 Louis W. Sullivan, M.D. / / FOR all / / Against
02 Stephen M. Simes 03 Victor Morgenstern nominees all
04 Fred Holubow 05 Ross Mangano listed nominees
06 Edward C. Rosenow III, M.D. 07 Angela Ho below listed
08 Peter Kjaer 09 Avi Ben-Abraham, M.D. below
(except as marked to the contrary below)
(INSTRUCTION: TO VOTE AGAINST ANY INDIVIDUAL NOMINEE, STRIKE A LINE THROUGH THE
NOMINEE'S NAME.)
2. AMENDMENT OF 1998 STOCK OPTION PLAN / / For / / Against / / Abstain
Proposal to amend the 1998 Stock Option Plan
to increase the number of shares of common
stock specifically reserved for issuance under
the plan by 2,000,000 shares, from 5,000,000
shares to 7,000,000 shares.
3. RATIFICATION OF AUDITORS / / For / / Against / / Abstain
Proposal to ratify the appointment of
Deloitte & Touche L.L.P. as independent
auditors for the fiscal year ending
December 31, 2000.
4. In their discretion, the proxies are authorized to vote upon such other
business, as may properly come before the meeting.
THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED Dated:_______________, 2000
IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED
SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY ___________________________
WILL BE VOTED FOR ALL NOMINEES NAMED IN PROPOSAL Signature
1 AND FOR PROPOSALS 2 AND 3.
___________________________
Signature if held jointly
Please sign exactly as name
appears below. When shares
are held by joint tenants,
both should sign. When
signing as attorney,
executor, administrator,
trustee or guardian, please
give full title as such. If
a corporation, please sign
in full corporate name by
President or other
authorized officer. If a
partnership, please sign in
partnership name by
authorized person.
PLEASE MARK, SIGN, DATE AND
RETURN THE PROXY CARD
PROMPTLY USING THE ENCLOSED
ENVELOPE.
<PAGE>
BIOSANTE PHARMACEUTICALS, INC.
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
JUNE 13, 2000
2:00 pm LOCAL TIME
AMERICAN AIRLINES
ADMIRALS CLUB
TERMINAL 3
O'HARE INTERNATIONAL AIRPORT
CHICAGO, ILLINOIS
BioSante Pharmaceuticals, Inc.
175 Olde Half Day Road
Lincolnshire, Illinois 60069 PROXY
- -------------------------------------------------------------------------------
THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS
The undersigned hereby appoints Stephen M. Simes and Phillip B. Donenberg and
each of them, as proxies, each with full power of substitution, and hereby
authorizes each of them to represent and to vote, as designated below, all
the shares of capital stock of BioSante Pharmaceuticals, Inc. held of record
by the undersigned on April 28, 2000, at the Annual and Special Meeting of
Shareholders to be held on June 13, 2000, or any adjournment thereof.
SEE REVERSE FOR VOTING INSTRUCTIONS.
